Shares of Clovis Oncology Inc. (CLVS) rose 5.1% to $76.02 ahead of the open on Friday, Sept. 8, as the Boulder, Colo.-based company is scheduled to present comprehensive data from its Phase 3 study of rucaparib at the European Society for Medical Oncology Congress in Madrid. The study showed rucaparib, a candidate to treat late-stage ovarian cancer, met its primary endpoint and key secondary endpoint. Professor Jonathan A. Ledermann, MD will present the data on Friday afternoon. Clovis shares traded down 1.3% after Friday's open.
Shares of NewLink Genetics Corp. (NLNK) continued to rise Friday after the Ames, Iowa-based firm on Thursday unveiled updated data from a Phase 2 study of its indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, indoximod, in tandem with Merck & Co. Inc.'s MRK PD-1 pathway inhibitor, Keytruda (pembrolizumab), to treat melanoma.
NewLink shares closed at $13.60 on Thursday, up 74.6%, and were up 33% to $18.10 in morning trading on Friday.
Meanwhile, shares of Incyte Corp. (INCY) were down over 4% to $128.37 after the Wilmington, Del.-based firm said it priced an underwritten public offering of 4.945 million shares. The company has given the underwriter an option to buy up to an additional 741,750 shares. Incyte said it plans to use the net proceeds for general corporate purposes.
More of What's Trending on TheStreet: